Search

Displaying results 931 - 940 of 4591 in total
  1. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  2. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  3. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [A274073] Tiratricol is currently being investigated in US clinical trials. … by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain.

  4. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times ...

  5. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.

  6. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with anemia of CKD but … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.

  7. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    Molnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of [N4-hydroxycytidine]. … [L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]

  8. Drug

    Methyltestosterone

    go.drugbank.com/drugs/DB06710
    ApprovedInvestigational

    Methyltestosterone is a schedule III drug in the US.

  9. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    [T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]

  10. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.